Trevi Therapeutics Inc (NASDAQ: TRVI) is 58.37% higher on its value in year-to-date trading and has touched a low of $2.30 and a high of $7.39 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The TRVI stock was last observed hovering at around $6.47 in the last trading session, with the day’s gains setting it 0.06%.
Currently trading at $6.53, the stock is 11.63% and 35.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.18 million and changing 0.85% at the moment leaves the stock 84.72% off its SMA200. TRVI registered 94.78% gain for a year compared to 6-month gain of 105.84%. The firm has a 50-day simple moving average (SMA 50) of $4.8062 and a 200-day simple moving average (SMA200) of $3.532325.
The stock witnessed a 44.68% loss in the last 1 month and extending the period to 3 months gives it a 60.71%, and is -1.29% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.60% over the week and 8.17% over the month.
Trevi Therapeutics Inc (TRVI) has around 26 employees, a market worth around $630.85M and $0.00M in sales. Distance from 52-week low is 183.70% and -11.71% from its 52-week high. The company has generated returns on investments over the last 12 months (-47.72%).
The EPS is expected to shrink by -11.80% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
143.0 institutions hold shares in Trevi Therapeutics Inc (TRVI), with institutional investors hold 87.09% of the company’s shares. The shares outstanding are 93.60M, and float is at 57.14M with Short Float at 8.19%. Institutions hold 86.27% of the Float.
The top institutional shareholder in the company is NEA MANAGEMENT COMPANY, LLC with over 11.37 million shares valued at $33.88 million. The investor’s holdings represent 11.2532 of the TRVI Shares outstanding. As of 2024-06-30, the second largest holder is FRAZIER LIFE SCIENCES MANAGEMENT, L.P. with 7.38 million shares valued at $22.0 million to account for 7.305 of the shares outstanding. The other top investors are RUBRIC CAPITAL MANAGEMENT LP which holds 5.03 million shares representing 4.9751 and valued at over $14.98 million, while VIKING GLOBAL INVESTORS LP holds 4.3546 of the shares totaling 4.4 million with a market value of $13.11 million.
Trevi Therapeutics Inc (TRVI) Insider Activity
The most recent transaction is an insider sale by SCIASCIA THOMAS, the company’s Chief Scientific Officer. SEC filings show that SCIASCIA THOMAS sold 2,631 shares of the company’s common stock on Mar 25 ’25 at a price of $6.60 per share for a total of $17365.0. Following the sale, the insider now owns 0.22 million shares.
Trevi Therapeutics Inc disclosed in a document filed with the SEC on Mar 21 ’25 that GOOD JENNIFER L (President & CEO) sold a total of 5,263 shares of the company’s common stock. The trade occurred on Mar 21 ’25 and was made at $6.58 per share for $34625.0. Following the transaction, the insider now directly holds 0.21 million shares of the TRVI stock.
Still, SEC filings show that on Mar 21 ’25, GOOD JENNIFER L (Officer) Proposed Sale 5,263 shares at an average price of $6.58 for $34625.0. The insider now directly holds shares of Trevi Therapeutics Inc (TRVI).
